Clario’s Oncology Webinar Series

Join this webinar series to discover how AI enhances diagnostic accuracy and provides prognostic insights and treatment assessment as well as understand the balance between AI-driven innovation and safeguarding patient privacy and data integrity in oncology clinical trials.

Participants will learn how electronic clinical outcome assessment (eCOA) equivalence studies have paved the way for accessibility functionality testing for oncology trials, discover accessibility features for scientific assessment on the potential impact on data integrity and hear about future endeavors to make accessibility a reality for trial participants.

The series will help viewers understand the unique aspects of assessing cardiac safety within an oncology development program, improve awareness of electrocardiogram (ECG) best practices, comprehend the importance of objective safety measurements with patient-reported outcomes and learn to enable early detection using wearable sensor technology to proactively monitor patients.

PART 1: TUESDAY, NOVEMBER 28, 2023 @ 11am – 12pm EST (recording available)

Revolutionizing Oncology Clinical Trials: The Transformative Power and Promise of AI-Enhanced Medical Imaging

The integration of artificial intelligence (AI) with medical imaging in oncology clinical trials has brought about a profound transformation. Its advancements have revolutionized diagnostic accuracy and prognostic insights with advanced image segmentation methods enabling precise delineation of pathological areas and enhancing treatment response measurements. Furthermore, AI’s predictive capabilities offer new avenues for anticipating disease progression and improving therapeutic strategies, all while ensuring patient privacy. Overall, the adoption of AI in oncology clinical trials promises a journey of innovation, encompassing precision diagnostics, predictive modeling and therapy evolution. This journey navigates complex aspects like patient privacy, data integrity and stakeholder engagement.

In this discussion, we will delve into the current advancements of AI that are enhancing the efficiency of oncology clinical trials with a focus on medical imaging. Additionally, we will explore the exciting potential that deep learning and generative AI hold in this dynamic field.

Join esteemed speakers, Kim Nguyen, Joel Schaerer and Alex Boudreau, to explore how AI is transforming medical imaging for oncology-focused clinical trials.

PART 2: MONDAY, DECEMBER 4, 2023 @ 11am – 12pm EST (upcoming live)

Using Scientific Validation to Move the Needle on Accessibility Functionalities

With the advance of technology, new opportunities to improve the clinical trial experience from a site and patient perspective come into existence. As regulatory bodies are demanding the use of accessibility functionality to improve inclusivity, Clario’s scientific team is currently assessing the level of scientific research required to validate the use of accessibility features such as zoom in/zoom out and ensure data integrity is maintained.

In the webinar, the presenters will discuss the accessibility features and present results to date on this industry’s first study and provide insight into the next steps for accessibility functionalities.

PART 3: WEDNESDAY, DECEMBER 13, 2023 @ 10am – 11am EST (upcoming live)

Integrating Objectively Measured Safety Endpoints and Patient-Reported Outcomes in Oncology Trials: A Scientific Approach

In the ever-evolving landscape of drug development within oncology, the importance of collecting high-quality data across multiple endpoints cannot be overstated. This data plays a pivotal role in determining the success of a drug. The integration of objective safety measurements with patient-reported outcomes is now essential in characterizing a drug’s safety profile, influencing overall benefit-risk considerations. Clario invites you to explore our comprehensive scientific approach to enhancing safety and tolerability assessments in oncology trials through this webinar.

Oncologic agents frequently exhibit cardiac toxicities, including left ventricular function depression, QTc prolongation and blood pressure elevation. This has given rise to the emerging field of cardio-oncology, dedicated to detecting and managing these risks within oncology development programs. Furthermore, as the focus on patient-centered drug development grows, recent regulatory guidelines now outline core patient-reported outcomes (PROs) to be incorporated into oncology clinical trials. Among these are self-reported symptomatic adverse events, with the 2023 draft FDA guidance emphasizing their importance in enhancing tolerability assessments, particularly in early-phase dose optimization trials.

Technological advancements in wearable sensor technology have introduced cutting-edge sensors and analytics capable of monitoring and analyzing patient mobility and activity levels during oncology trials. This proactive approach facilitates the early detection of safety concerns, further enhancing patient safety and data integrity.

Join us in expanding your knowledge and contributing to the advancement of patient safety and data quality within the field of oncology research.